Home Agendia Inc

Agendia Inc

Publication of Study Validating Use of MammaPrint and BluePrint Molecular Diagnostics using Targeted RNA Next-Generation Sequencing Technology

Agendia Inc June 20, 2019

MammaPrint and BluePrint Molecular Diagnostics using targeted RNA Next-Generation Sequencing technology has been published in the Journal of Molecular Diagnostics.

LEARN MORE

New Studies Show MammaPrint® and BluePrint® Tests Provide Greater Clarity Regarding Risk of Breast Cancer Recurrence and Classifications for Treatment

Agendia Inc December 7, 2018

12/7/18: BluePrint reclassified 85 percent of tumors identified as HER2-amplified by IHC/FISH to non-HER2 molecular subtype and clarified the biology of HER2 "equivocal" breast cancer. 46 percent of women under 50 years of age with an intermediate recurrence score identified as MammaPrint Low Risk enabling greater certainty in treatment management approaches

LEARN MORE

RECENT COMMENTS

Prof Sherif Sultan on Perfect AAA EVAR Stent Has Not Been Designed or Produced: All Current AAA EVAR Devices are Obsolete

Khaled mohamed fekry saleh on Perfect AAA EVAR Stent Has Not Been Designed or Produced: All Current AAA EVAR Devices are Obsolete

Medical Device News Magazine on Neurolief’s Relivion™ Digital Therapeutics Brain Neuromodulation Technology Featured at Headache Symposium in Israel

Paula on Neurolief’s Relivion™ Digital Therapeutics Brain Neuromodulation Technology Featured at Headache Symposium in Israel

Helen on New Study Validates Rigorous Safety Measures Needed To Reduce Mercury Exposure During Dental Amalgam Filling Removal

JP on Groundswell Pushing FDA to Stop Mercury Amalgam Use in Children: Op-Ed

Teresa Franklin on Groundswell Pushing FDA to Stop Mercury Amalgam Use in Children: Op-Ed

Cynthia Easter on Groundswell Pushing FDA to Stop Mercury Amalgam Use in Children: Op-Ed

Rob Abbot on Groundswell Pushing FDA to Stop Mercury Amalgam Use in Children: Op-Ed

Teresa Franklin on Groundswell Pushing FDA to Stop Mercury Amalgam Use in Children: Op-Ed

Eugenia McGrath on Groundswell Pushing FDA to Stop Mercury Amalgam Use in Children: Op-Ed

Helen on Groundswell Pushing FDA to Stop Mercury Amalgam Use in Children: Op-Ed

Molly Hauck on Groundswell Pushing FDA to Stop Mercury Amalgam Use in Children: Op-Ed

Eric Uram on Groundswell Pushing FDA to Stop Mercury Amalgam Use in Children: Op-Ed

Patrick on Groundswell Pushing FDA to Stop Mercury Amalgam Use in Children: Op-Ed

Michael Bender on Groundswell Pushing FDA to Stop Mercury Amalgam Use in Children: Op-Ed

ganka on New Cochlear™ Nucleus Sound Processor® Profile™ Plus Series Cochlear Implant and Nucleus 7 Sound Processor Receive FDA Approval

Airtech Equipment Pte Ltd on Leaf Healthcare, Inc. Acquired by Smith & Nephew

Harry on Experts Discuss How They’ve Adopted TransCarotid Artery Revascularization (TCAR)

Juan C Parodi on From Resistance to Standard of Care: Gaining Acceptance for Technology to Prevent Stroke

Bergantini Hélio on First Patient Treated in First-in-Man Study of Deep Vein Thrombosis Treatment Designed to Remove Wall-Adherent Clot in Single Session, without Thrombolytic Drugs

Osama on First Patient Treated in First-in-Man Study of Deep Vein Thrombosis Treatment Designed to Remove Wall-Adherent Clot in Single Session, without Thrombolytic Drugs

dr.ashwin bhammar on From Resistance to Standard of Care: Gaining Acceptance for Technology to Prevent Stroke

Ilene on From Resistance to Standard of Care: Gaining Acceptance for Technology to Prevent Stroke

Amy Lewis on From Resistance to Standard of Care: Gaining Acceptance for Technology to Prevent Stroke

M Subramaniam on Negative Abdominal Aortic Aneurysm NICE Guidelines is A Step Backward: Don’t be Fooled by Them

Harry on Negative Abdominal Aortic Aneurysm NICE Guidelines is A Step Backward: Don’t be Fooled by Them

Sherif on Negative Abdominal Aortic Aneurysm NICE Guidelines is A Step Backward: Don’t be Fooled by Them